Asset profile
MN-001
Unknown / undisclosed
Evidence outlook · lead readout
NCT02681055 · Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease,...
The reported results come from study designs that frequently fail to replicate under controlled conditions; see the rationale below.
NCT02681055: Every subject received the drug in this open-label study with no placebo or comparator arm, so any change observed cannot be attributed to the drug rather than natural history or expectation; the small reported changes in cholesterol efflux capacity and triglycerides were not tested against a control group.
Also in development:Type 2 Diabetes · Phase 2NASH · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
116 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication; 116 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| MN-001: this drug | Phase 2 | — | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) |
…and 101 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.